- Home
- JMIA vs AVXL Comparison
JMIA vs AVXL Comparison
Compare JMIA & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMIA
- AVXL
- Stock Information
- Founded
- JMIA 2012
- AVXL 2004
- Country
- JMIA Germany
- AVXL United States
- Employees
- JMIA N/A
- AVXL N/A
- Industry
- JMIA Catalog/Specialty Distribution
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JMIA Consumer Discretionary
- AVXL Health Care
- Exchange
- JMIA Nasdaq
- AVXL Nasdaq
- Market Cap
- JMIA 949.1M
- AVXL 956.7M
- IPO Year
- JMIA 2019
- AVXL N/A
- Fundamental
- Price
- JMIA $9.91
- AVXL $9.37
- Analyst Decision
- JMIA Hold
- AVXL Strong Buy
- Analyst Count
- JMIA 1
- AVXL 2
- Target Price
- JMIA $4.75
- AVXL $44.00
- AVG Volume (30 Days)
- JMIA 4.2M
- AVXL 987.3K
- Earning Date
- JMIA 11-06-2025
- AVXL 08-12-2025
- Dividend Yield
- JMIA N/A
- AVXL N/A
- EPS Growth
- JMIA N/A
- AVXL N/A
- EPS
- JMIA N/A
- AVXL N/A
- Revenue
- JMIA $164,022,000.00
- AVXL N/A
- Revenue This Year
- JMIA $14.49
- AVXL N/A
- Revenue Next Year
- JMIA $17.02
- AVXL N/A
- P/E Ratio
- JMIA N/A
- AVXL N/A
- Revenue Growth
- JMIA N/A
- AVXL N/A
- 52 Week Low
- JMIA $1.60
- AVXL $5.03
- 52 Week High
- JMIA $10.28
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- JMIA 68.09
- AVXL 45.30
- Support Level
- JMIA $8.72
- AVXL $8.82
- Resistance Level
- JMIA $9.35
- AVXL $10.40
- Average True Range (ATR)
- JMIA 0.60
- AVXL 0.53
- MACD
- JMIA 0.02
- AVXL 0.03
- Stochastic Oscillator
- JMIA 85.48
- AVXL 34.81
About JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.